SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is a top trending stock following its recent earnings report, which showed stronger-than-expected results for the past quarter but included a weaker outlook for the current period due to supply constraints and manufacturing yields. This mixed news has sparked a fervent debate among investors, with many long-term bulls seeing a buying opportunity in the face of temporary challenges, citing the company's AI initiatives, advanced 18A node, and government backing for its foundry efforts. However, others remain cautious, pointing to the soft guidance as evidence of ongoing competitive struggles and concerns about the stock's valuation after its recent strong rally.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is surging with strong buying interest, as the stock has rallied past key technical resistance levels and achieved a notable close. This momentum is largely driven by investor anticipation following its FDA Breakthrough Therapy Designation for Pemvidutide, fueling widespread speculation of an imminent partnership or acquisition in the active GLP-1/MASH sector. The community is also keenly watching for a potential short squeeze and increased institutional investment now that the stock is trading above $5.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is generating significant buzz across trading communities, primarily driven by strong short-squeeze potential attributed to its exceptionally low public float and escalating buying interest. Traders are actively discussing the ongoing strategic review and the company's substantial cash position as key factors that could ignite a significant upward movement.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is experiencing significant speculative interest following its merger announcement with Corvex, an AI cloud computing firm. The catalyst is Corvex's newly secured long-term NVIDIA H200 GPU deployment, fueling community discussion around a potential short squeeze given MOVE's notably low share float. While many anticipate substantial upward movement from the AI and NVIDIA association, others are exercising caution regarding the merger's valuation specifics and potential for volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as the community eagerly anticipates its upcoming earnings report on February 3rd. The absence of a pre-earnings business update, unlike prior quarters, is widely seen as a bullish indicator, fueling speculation about a potential beat and igniting calls for a short squeeze. Despite lingering gross margin discussions and recent analyst downgrades, investors are focused on SMCI's critical role and perceived undervaluation in the rapidly expanding AI infrastructure market.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid positive developments surrounding its ANKTIVA cancer treatment, including advancements in regulatory resubmission discussions and international approvals. The community is intensely focused on the stock's remarkable streak of consecutive green days and a perceived short squeeze, fueled by high borrowing costs for short sellers and strong belief in the company's long-term potential in cancer therapy.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares are trending as Goldman Sachs recently raised its price target for gold, fueling bullish sentiment. The community is actively debating whether ongoing geopolitical tensions and concerns over fiat currency debasement will drive further record highs or if current overbought conditions signal an impending correction for the popular safe-haven asset.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $150 million direct offering of common shares, sparking widespread discussion. While some investors express concern over dilution and a perceived lack of immediate commercialization news, many see this capital raise as a strategic, bullish move. The community anticipates the funds will accelerate production capabilities and facilitate potential acquisitions like Sivers Semiconductors, positioning POET to meet future demand for its optical interposer technology in the rapidly growing AI data center market, further bolstered by a recent product innovation award.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following a recent robust earnings report, which highlighted significant procedure growth and revenue beats from its da Vinci and Ion systems. While many investors are optimistic about the company's continued market dominance and innovative advancements like AI integration, the community is actively debating its high valuation and potential impacts from tariffs or GLP-1 drugs on certain surgical volumes. This has created a dynamic conversation around the company's strong operational performance balanced against its premium market multiple.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Analysts at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve research firms that are presently covering the firm, Marketbeat...

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on January 12th, the Representative disclosed that...

Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline

Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its outlook for 2026, highlighting a new thalassemia launch, continued...

JPMorgan Chase & Co. Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $25.00

JPMorgan Chase & Co. raised their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday...

Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells 2,932 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average...

Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 2,932 shares of the company's stock in a transaction dated Tuesday, December 30th. The shares were sold at an...

Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,932 shares of the company's stock in a transaction dated Tuesday, December 30th. The stock was sold at an...

Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 18,703 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average...

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Should You Sell?

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Time to Sell...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AGIO News

AGIOAgios Pharmaceuticals Inc